caused by the bounded scale. Various analytical approaches have recently been proposed for use in cross-sectional studies, however, less attention is paid to longitudinal designs. We examined the use of beta regression models to analyze HRQL data over time using two empirical examples. METHODS: The HRQL measures employed in our empirical examples were the generic SF-6D and the disease-specific Stroke Impact Scale (SIS). Data came from the German KORA cohort study and from a clinical setting, respectively. We fitted mixed and marginal beta models and explain the conceptual difference between these two model classes, namely the population-averaged and the subject-specific perspective. We compared overall fit and predictive accuracy of the models to the commonly used linear mixed model (LMM). RESULTS: The SF-6D data were highly skewed to the left and the SIS data exhibited a pronounced ceiling effect. In both examples, the beta distribution fitted the data better than the normal distribution. Beta regression accounted for the fact that predicted values must fall into the bounded support of the scales and overall fit measures suggested that the mixed beta model was superior to the LMM (AIC: Ϫ2723 vs. Ϫ2441 and Ϫ904.1 vs. Ϫ376.4). However, mixed beta regression underestimated the mean at the upper part of the distribution. Adjusted group mean scores from the marginal beta model were nearly identical to those derived from the LMM. CONCLUSIONS: Longitudinal beta regression models are potential candidates to analyze HRQL over time since they account for the specific characteristics such data typically have. However, our results show that in practice, estimates may only differ slightly from those of commonly used methods. 
OBJECTIVES:
The Minnesota Living with Heart Failure Questionnaire (MLHFQ) is one of the most used specific instruments for measuring quality of life in patients with heart failure. It comprises 21 items conforming a total score, as well as two domains: the physical and the emotional. The aim of this study was to evaluate the reliability, validity, and responsiveness of the Spanish MLHFQ. METHODS: Patients completed the MLHFQ and the SF-12 during their hospitalization for heart failure (nϭ1175), and 6 months after discharge (nϭ473). Reliability was assessed by Cronbach's alpha coefficient. Confirmatory factor analysis (CFA) for categorical variables was used to study construct validity. Convergent validity was assessed by correlations between MLHFQ and SF-12 scales. To study known-groups validity, MLHFQ at 6 months were compared according to readmission. Responsiveness was evaluated by effect sizes and according to patients classified as improved, equal, or worsened than at baseline. RESULTS: Cronbach's alpha was Ն0.80 for the three domains. CFA confirmed the two factor model, with factor loadings ranging from 0.56 to 0.87. Both Tucker-Lewis and Comparative Fit indexes were Ͼ0.90, but the root mean squared error of approximation was Ͼ0.08. The highest correlations were obtained between MLHFQ and SF-12 physical domains (rϭϪ0.55), and between the emotional MLHFQ and mental SF-12 domain (rϭϪ0.53), supporting the convergent validity. Known-groups validity was shown with significantly worse scores within patients with readmission (PϽ0.0001). Responsiveness parameters among improved patients were 1.20 and 1.05 for physical and total score, respectively, indicating large changes, and 0.59 for emotional domain, indicating moderate changes. CONCLUSIONS: The Spanish MLHFQ is valid, reliable and responsiveness 6 months after discharge for patients hospitalized with heart failure. Because its simplicity and ease of application, it may be useful in routine practice and clinical research. Further, its cross-cultural characteristics make it very useful for comparisons among countries. 
PRM136

OBJECTIVES:
To propose a single score for quality of life (QoL) derived from the SF-36 and the HAQ in patients with APS in a tertiary care center. METHODS: It is a cohort study. Sample was stratified in two groups according to the numbers of changes in the warfarin dosage over a period of 12 months: Group 1 (Ͻ 6 changes in 12 months) and Group 2 (Ͼ 6 changes in 12 months). This change was due to INR oscillation. To assess quality of life, SF-36 and HAQ instruments at baseline and after 12 months of follow-up were used. To derive the single score, a descriptive analysis evaluated the variables. Principal component analysis (PCA) was done to reveal the internal data structure that explains the data variance. APS score was calculated by the sum of the values obtained by weighting the factor scores for each component by the proportion of variability explained by the respective component. To measure APS score consistency to patient's preference, we based on the hypothesis that Group 2 had a worse quality of life. To test it, we evaluated APS score into the two time points. To corroborate these results, we applied repeated measures ANOVA technique. For all statistical tests, the significance level used was Ͻ 5%. 
To administer a questionnaire to 14,000 women in order to measure various aspects of women's lifestyle, including sensitive habits, and health. METHODS: A first population-based mailing was sent to around 31,000 women, inviting them to complete a questionnaire on a dedicated website or on paper. Women who did not initially respond were reminded to complete the questionnaire first through an additional mailing and then, for the ones who had still not responded, through telephone calls. During the second reminder, they were also offered the possibility to complete the questionnaire over the telephone. Each reminder was performed after a 3-week waiting period. RESULTS: Among the 30,917 women contacted, 26.0% completed initially the questionnaire. After the first reminder, the questionnaire was completed by 18.6% of the women who did not respond to the first mailing and, after the second reminder, by 24.2% of the women who did not respond after the first reminder. The first mailing followed by the two reminders resulted in a 52.4% completion rate of the questionnaires. Questionnaires received after the first mailing, then after the first and second reminder accounted for respectively 49.6%, 26.9% and 23.4% of the total amount of completed questionnaires. When offered the possibility to complete the questionnaire on paper or on a dedicated website, only 18.8% of the women choose the on-line method. During the telephone call of the second reminder, when offered the possibility, most women agreed to complete the questionnaire over the telephone (53.7%). CONCLUSIONS: The methodology employed resulted in an overall good completion rate (52.4%). The objective of 14,000 completed questionnaires would have not been achieved without proactive and direct to subject contacts using reminders, including telephone contacts, allowing finally a two-fold increase of the initial responders rate. 
RESEARCH ON METHODS -Statistical Methods
PRM138 A PROPENSITY TO GET IT RIGHT. A MONTE CARLO SIMULATION STUDY COMPARING STATISTICAL METHODS TO OBTAIN CORRECT COST-EFFECTIVENESS ESTIMATES IN OBSERVATIONAL STUDIES
OBJECTIVES:
Estimates of real-world cost-effectiveness are mostly based on observational data with non-random treatment assignments. Several methods exist to address the resulting confounding-by-indication, including regression and methods based on propensity scores (PS). This study examined the performance of these methods in the context of cost-effectiveness analysis. The PS-methods were: PS matching (kernel and one-to-one), covariate adjustment using PS, inverse probability-of-treatment weighting (IPTW) and double robustness, each with several specifications. METHODS: Thirty-eight adjustment approaches were compared using Monte Carlo simulations. In each simulation, four differently confounded samples (nϭ2000) were drawn from a synthesized population. Incremental survival time and costs were calculated using the results of Weibull survival and generalized linear regression. These regressions -with treatment as sole covariate or fully specified with all confounders -were performed directly or after applying a PSmethod. Each approach was assessed on bias (systematic deviation from the true effect), accuracy (proportion of simulated results within acceptable distance from the true values) and reliability (width of bootstrapped confidence intervals) of estimates of incremental effects, costs and cost-effectiveness ratios. RESULTS: In estimates of the average treatment effect in the treated (ATT), kernel and 1-to-1 PS matching had similar bias and accuracy results, but the reliability of kernel was better. Regarding average treatment effects for the sample as a whole (ATE), double robustness and IPTW had the least bias and the best accuracy and reliability. Combining PS methods with fully specified regression models was most likely to lead to good results. PS covariate adjustment and regression without a PS method scored worst. CONCLUSIONS: PS methods are preferable to conventional regression for use in observational cost-effectiveness studies. Combining a PS method with fully specified regression should be considered for the analysis. Since no method is always superior, it is advised that sensitivity analyses with different techniques be performed. 
PRM139 INCLUDING PATIENTS IN MULTIPLE GROUPS AND MULTIPLE TIMES IN THE SAME GROUP IN LONGITUDINAL OBSERVATIONAL RESEARCH: A CYSTIC FIBROSIS EXAMPLE
OBJECTIVES:
In longitudinal observational studies, patients can meet eligibility criteria for more than one group and can be eligible multiple times for the same group. We used Epidemiologic Study of Cystic Fibrosis data to explore different inclusion decisions when evaluating dornase alfa treatment. METHODS: The dornase alfa group included patients enrolled Ն2 years before starting consistent dor-A485 nase alfa therapy. A lung function test ("index") separated a 2-year pre-index period from a 2-year post-index period for which intercepts and slopes were independently estimated. The comparator group included patients not yet reported to have received dornase alfa; their index lung function test was associated with their eighth or subsequent even-numbered birthday. Comparator patients could contribute more than one set of pre-and post-index periods and could also subsequently be included in the dornase alfa group. To account for the repeated use of patients, variance components were estimated at the patient level as well as the case level. Different subsets of the comparator cases were analyzed. RESULTS: There were 2230 dornase alfa patients; the comparator group included 5970 cases from 3517 patients. The estimated difference in change in slope was 0.73Ϯ.31 (Pϭ0.020). Subsetting comparators to 4985 cases from 2836 patients not also in the dornase alfa group gave 0.61Ϯ0.32 (Pϭ0.058); including each of those patients only the last time eligible gave 0.68Ϯ0.36 (Pϭ0.059). Subsetting to 3662 cases from 2030 patients never on dornase alfa gave 0.32Ϯ0.34 (Pϭ0.35). Patient-level variance components corresponding to difference in slope and difference in intercept were near zero and so were dropped. CONCLUSIONS: In longitudinal observational studies, patients should be included in each group for which they meet eligibility criteria, possibly multiple times (with appropriate covariance structures). This avoids bias from using future information to decide whether to include a patient and loss of power from limiting cases unnecessarily. Numerous assumptions and techniques are necessary to perform meta-analysis. Some overall structural guidelines and best practices on meta-analysis exist. However, few papers compare meta-analysis techniques in application. OBJECTIVES: To review primary meta-analysis methods and their assumptions. After methodology review, we applied various meta-analysis techniques to the data of various Bacille Calmette Guerin (BCG) vaccine studies and compared the results. METHODS: Of the currently available meta-analysis techniques, the most basic technique was applied first. Fixed effect models assume treatment effect homogeneity across studies. Then, random effect models and meta-regression were explored. Each technique explicitly models treatment heterogeneity. Lastly, the possibility of publication bias was tested through the use of a funnel plot. RESULTS: Treatment effect estimates differed depending on the meta-technique applied. When a fixed effect model was applied to estimate vaccination effectiveness against tuberculosis, the log odds ratio was Ϫ0.436 (confidence interval [CI]: Ϫ0.528, Ϫ0.344). After testing for heterogeneity and fitting a random effects model, the estimate was reduced to Ϫ0.741 (CI: Ϫ1.120, Ϫ0.352), and the CI became wider. When covariates were added to the model to explain the heterogeneity, the effect of treatment was reduced even further. CONCLUSIONS: Meta-analysis results are sensitive to the selected studies and the methodology applied. Ensuring that proper techniques are used is critical to estimate an unbiased outcome. 
PRM140 AN APPLIED COMPARISON OF META-ANALYSIS TECHNIQUES USING BACILLE CALMETTE GUERIN VACCINE STUDIES
PRM141 COMBINING AN ORDERED LOGIT MODEL WITH INDIVIDUAL PATIENT-LEVEL DATA TO ROBUSTLY ESTIMATE WITHIN-CATEGORY VISUAL ACUITY STARTING DISTRIBUTIONS: AN INNOVATIVE MODELING APPROACH IN THE CASE OF VITREOMACULAR TRACTION
OBJECTIVES:
The ISPOR Task force (TF) on Good Research Practices for RCT-CEA aims to foster improvements in the conduct of trial-based economic analysis. The TF recognizes the sample size of randomized clinical trials (RCT) as one of the challenges for trial-based economic analysis, as it is typically based on the primary clinical outcomes only. In the case of vitreomacular traction (VMT), using RCT individual patient-level data (IPD) to establish model starting distributions within visual acuity (VA) health-states magnifies this challenge due to the small patient numbers within each relevant VA health-state. Our objective was to develop an innovative approach to robustly estimate patient within-category VA health-state starting distributions. METHODS: A baseline VA-adjusted ordered logit model used RCT IPD to predict a patient's VA starting distribution as a function of treatment allocation, macular hole, vitreomacular adhesion and previous vitrectomy status. The observed ordinal variable consisted of 6 response categories i.e. VA state as a function of an unmeasured, continuous, latent variable Y whose values determine the patient's VA-state dependent specific VA thresholds. RESULTS: Treatment allocation was not a significant predictor for within-category VA health-state starting distributions (at the 5% significance level), while MH, VMA and previous vitrectomy status were significant and retained in the final model. The proportional odds assumption was tested using a likelihood ratio test and confirmed that the relationship between each pair of VA health-states was the same (chi2 ϭ 0.0906). CONCLUSIONS: In eye-disorders like VMT, estimating within-category VA healthstate starting distributions requires a different approach due to the small number of IPD in each VA health-state. Using an ordered logit model allows a more accurate and robust estimation of within-category VA health-state starting distributions. Macular hole, VMA and previous vitrectomy status were significant predictors of a patient's within-category VA health-state starting distribution, while treatment allocation was not. 
PRM142 USE OF BODY SURFACE AREA AS A DETERMINANT OF DOSE IN CANCER STUDIES
OBJECTIVES:
With the lack of alternative strategies for calculating the dose of cytotoxic drugs in chemotherapy regimens, body surface area (BSA), despite welldocumented limitations, remains the most frequently used measure for dosing guidelines. This is based on the assumption that physiological variables related to drug metabolism and elimination, such as basal metabolic rate, renal and hepatic function, vary between individuals according to BSA. BSA has traditionally been calculated using a formula derived from Du Bois and Du Bois and published in 1916. It is recognised this is probably not the most accurate method of calculating chemotherapy doses, since the formula was derived from metabolic studies using a small number of subjects. The practice of calculating chemotherapy dose adjusted to BSA has drawn attention due to its lack of clear scientific basis, and lack of applicability to different genders, disease states, and culture. METHODS: A systematic literature review was conducted using CRD methodology to establish the average BSA in cancer patients in Europe and the variability between genders, tumour types, and cultures. RESULTS: Meta-analysis of the findings showed significant differences between genders overall (females 1. 
In the context of today's highly globalized environment, the interest in the transferability of data of cost evaluation in health care has strongly intensified. A methodology is proposed to explore similarity versus dissimilarity of cost evaluation data in adult sarcoma and hence their transferability across locations (France and Italy). METHODS: Main steps are (i) definition of the objects (e.g. countries), identification of potential variability factors, selection of final variability factors, and construction of variability areas (e.g. unit cost of personnel); (ii) measure of distances between the objects, determination of clusters and construction of a hierarchical tree using the cluster analysis (CA); (iii) projection of the objects into factorial planes and linkage between objects and areas of variability using principal component analysis (PCA). Suggested methods are applied to an international cost evaluation performed within the European network of excellence CONnectiveTIssuesCAncersNETwork (CONTICANET). RESULTS: Twelve objects and 16 areas of variability were defined. CA shows four clusters meaning that data belonging to different clusters are dissimilar (i) chemotherapy in France, (ii) follow-up with relapse in Italy, (iii) diagnosis, surgery, chemotherapy, radiotherapy, and follow-up without relapse in Italy, (iv) diagnosis, surgery, radiotherapy, follow-up without relapse, and follow-up with relapse in France. PCA opposes (i) follow-up with relapse in Italy to diagnosis, radiotherapy, and follow-up with relapse in France; (ii) chemotherapy in France to follow-up without relapse in France. In sarcoma patients, transferability is then limited for chemotherapy during the initial treatment in France and the follow-up with relapse in Italy. Diagnosis cannot be transferred either between France and Italy regarding the quantities and unit costs of the biopsies. CONCLUSIONS: Using CA and PCA enables health care professionals to rapidly emphasize the variability of data and therefore to determine the transferability of cost evaluations across locations. 
PRM144 CARDIOLOGISTS' KNOWLEDGE AND AWARENESS OF GUIDELINES FOR MEDICAL DEVICE SAFETY AND PRODUCT RISK MANAGEMENT
OBJECTIVES:
To investigate the knowledge, awareness and attitudes of cardiologists about the risk and benefits associated with medicines and medical devices and equipment, and of how well they are regulated and communicated in Turkey. METHODS: An on -line questionnaire has been developed which include questions about the level of education and experience; perceptions of the risks and benefits associated with medicines and medical devices; experiences of medicines and medical devices; perceptions of and attitudes towards the regulation of medicines and medical devices; attitudes towards the communication of information about the risks and benefits associated with medicines and medical devices; usage of and trust in communication of information about the risks and benefits associated with medicines and medical devices. RESULTS: A total of 250 members of the Turkish A486
